VIRGINIA RETIREMENT SYSTEMS ET Al Purchases Shares of 113,568 Aurinia Pharmaceuticals Inc $AUPH

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 113,568 shares of the biotechnology company’s stock, valued at approximately $1,927,000. VIRGINIA RETIREMENT SYSTEMS ET Al owned about 0.09% of Aurinia Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. BOK Financial Private Wealth Inc. acquired a new position in shares of Aurinia Pharmaceuticals during the 4th quarter worth approximately $32,000. Nykredit A S acquired a new stake in Aurinia Pharmaceuticals during the 2nd quarter valued at $35,000. Global Retirement Partners LLC acquired a new stake in Aurinia Pharmaceuticals during the 2nd quarter valued at $41,000. Quantbot Technologies LP purchased a new position in Aurinia Pharmaceuticals during the second quarter worth $45,000. Finally, Allworth Financial LP purchased a new position in Aurinia Pharmaceuticals during the second quarter worth $56,000. 36.83% of the stock is owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Trading Down 0.1%

Shares of Aurinia Pharmaceuticals stock opened at $16.10 on Friday. Aurinia Pharmaceuticals Inc has a fifty-two week low of $10.34 and a fifty-two week high of $19.25. The firm has a market cap of $2.14 billion, a PE ratio of 7.03 and a beta of 1.40. The business’s fifty day moving average is $15.81 and its two-hundred day moving average is $15.61. The company has a quick ratio of 4.97, a current ratio of 5.42 and a debt-to-equity ratio of 0.07.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.04. The business had revenue of $58.57 million during the quarter, compared to the consensus estimate of $80.45 million. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%. Analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.79 earnings per share for the current year.

Wall Street Analyst Weigh In

AUPH has been the topic of several recent research reports. Zacks Research downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 21st. Royal Bank Of Canada lifted their price objective on Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research report on Friday, August 7th. Bloom Burton raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. Weiss Ratings upgraded shares of Aurinia Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 26th. Finally, Wall Street Zen cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Aurinia Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $17.67.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.